|
Market Research Report
Johnson & Johnson: Pipeline * Products * Performance * Potential
|
Johnson & Johnson:
Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in August, 2009. This report consists of Pages: 182 and the price starts from US $ 1040.
Abstract
Johnson & Johnson's operating activities are conducted within three business
segments: Medical Devices & Diagnostics, Pharmaceutical and Consumer. This
report provides a full review of the company's pharmaceutical activities.
Johnson & Johnson, through more than 230 operating companies, manufactures and
sells a broad range of products in the healthcare field for the
pharmaceutical, consumer, and medical devices and diagnostic markets to most
countries of the world. The company is organised on the principles of
decentralised management.
Current Growth Drivers
Within the Pharmaceutical segment in 2005, strong sales performances were
demonstrated by Risperdal and Risperdal Consta, Remicade, Topamax and Levaquin.
Key Late-Stage Products
Virology is a relatively new area of focus for J&J and it is currently
developing three HIV compounds of which TMC114, the most advanced compound,
has been filed. Candidates in Phase III trials include:
- Ceftobiprole for complicated skin and skin structure infections and
nosocomial pneumonia. Both indications have been granted fast track
designation by the FDA.
- Doripenem, a broad-spectrum antibiotic for complicated urinary tract
infections, complicated intra-abdominal infections and nosocomial pneumonia.
- BAY 59-7939 (Factor Xa inhibitor) for venous thromboembolism prevention
after major orthopaedic surgery (hip and knee).
Table of Contents
Principal Operating Results
Johnson & Johnson
Latest Results
Executive Summary
- Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- Capital Expenditure By Business Area, 2005
- R&D Expenditure
- Pharmaceutical R&D To Total R&D
- Pharma R&D and Pharma R&D to Pharma Sales
- Divisional Performance
- Sales By Business Area
- Sales By Business Area
- Operating Profit By Business Area
- Operating Profit By Business Area
- Identifiable Assets By Business Area
- Identifiable Assets By Business Area
- Geographic Performance
- Sales By Destination
- Sales By Destination
- Long-Lived Assets By Geographical Area
- Long-Lived Assets By Geographical Area
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Medical Devices and Diagnostics Segment
- Pharmaceutical Segment
- Consumer Segment
- Key Agreements
- Product / R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecasts
- Sales of Current Top Ten Products (2000A-2010E)
- Conclusions
PRODUCT PORT FOLIO / RESEARC H AND DEVELOPMENT
- Major Pharmaceutical Products, Therapeutic Areas and Sales
- Sales of Major Pharmaceutical Products, 2005
- R&D Pipeline
- Central Nervous System - Products
- Major Launched Products
- Risperdal
- Sales
- Key Markets/Indications/Formulations
- Generic Competition/Lawsuits
- Safety Issues
- Sales Forecast
- Risperdal Sales (2000A-2010E)
- Clinical Trial Results - Autism
- Duragesic/Ionsys
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Generic Competition
- Lawsuits
- Safety Issues
- Sales Forecast
- Duragesic Sales (2000A-2010E)
- Topamax
- Mode of Action
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Safety Information
- Sales Forecast
- Clinical Trial Results
- Ultram/Ultracet
- Markets/Indications/Formulations
- Generic Competition
- Razadyne
- Mode of Action
- Key Markets/Indications/Formulations
- Competitor Products
- Lawsuits
- Safety Issues
- Concerta
- Sales
- Safety Studies
- Generic Competition
- Clinical Trials
- Central Nervous System - R&D
- OROS hydromoprhone
- Paliperidone
- Tapentadol
- Central Nervous System - Summary
- Gastrointestinal - Products
- Major Launched Products
- Pariet/Aciphex
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Aciphex/Pariet Sales (2000A-2010E)
- Others
- Gastrointestinal - Summary
- Immunology - Products
- Major Launched Products
- Remicade (TA-650)
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Safety Issues
- Sales Forecast
- Remicade Sales (2000A-2010E)
- Clinical Trial Results - Paediatric Crohn's Disease
- Orthoclone OKT3
- Immunology - R&D
- Immunology - Summary
- Haematology - Products
- Major Launched Products
- Eprex/Procrit
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Safety Information
- Sales Forecast
- Eprex/Procrit Sales (2000A-2010E)
- Haematology - R&D
- Haematology - Summary
- Anti-infective - Products
- Major Launched Products
- Floxin
- Key Markets/Indications/Formulations
- Generic Competition
- Levaquin
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Generic Competition
- Sales Forecast
- Levaquin/Floxin Sales (2000A-2010E)
- Sporanox/Itrizole
- Sales
- Key Markets/Indications/Formulations
- Generic Competition
- Sales Forecast
- Sporanox Sales (2000A-2010E)
- Anti-infective - R&D
- Ceftobiprole
- Doripenem
- TMC114
- TMC125
- Anti-infective - Summary
- Oncology - Products
- Doxil/Caelyx
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits
- Clinical Trial Results
- Velcade
- Key Markets/Indications/Formulations
- Further Development
- Clinical Trial Results - Lymphoma
- Others
- Oncology - R&D
- Anti-IL-6 MAb
- UHRF1
- Yondelis
- Zarnestra
- Oncology - Summary
- Cardiovascular - Products
- Retavase
- Key Markets/Indications/Formulations
- Clinical Trial Results
- ReoPro
- Key Markets/Indications/Formulations
- Further Development
- Safety Issues
- Natrecor
- Key Markets/Indications/Formulations
- Further Development
- Lawsuits
- Safety Issues
- Clinical Trial Results
- Cardiovascular R&D
- Cardiovascular - Summary
- Reproductive Health - Products
- Ortho Evra
- Mode Of Action
- Key Markets/Indications/Formulations
- Safety Issues
- Reproductive Health - R&D
- Reproductive Health - Summary
- Other - R&D
APPENDIX 1 - FINANCIA L PERFORMA NCE
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- Ablynx
- AdipoGenix Inc
- Amgen
- 18th October 2002
- 24th January 2003
- 12th December 1996
- 1st January 1997
- 18th January 2006
- Arena Pharmaceuticals Inc
- 21st December 2004
- 23rd December 2004
- 11th August 2005
- 7th February 2006
- Barrier Therapeutics
- 10th May 2002
- 22nd September 2005
- Basilea Pharmaceutica AG
- Bayer
- 5th April 2000
- 10th May 2000
- 26th October 2005
- Biovail Corporation International
- 15th September 1998
- 3rd November 2005
- 2nd December 2005
- Cara Therapeutics Inc
- Cellzome Inc
- 16th March 2005
- 23rd May 2005
- Crucell NV
- 24th December 2002
- 16th January 2003
- 23rd November 2005
- Curis Inc
- Eisai
- 15th April 1997
- 16th March 2000
- 7th January 2004
- Eli Lilly
- Entelos Inc
- Ferring Pharmaceuticals Inc
- GlaxoSmithKline
- 12th July 2000
- 7th January 2002
- 20th July 2005
- Grunenthal GmbH
- 10th October 2003
- 28th April 2006
- GTx Inc
- Icagen Inc
- ImClone Systems Inc
- ImmunoGen Inc
- 28th December 2004
- 29th March 2004
- Kyowa Hakko
- Medivir AB
- Mitsubishi Pharma Corporation
- Millennium Pharmaceuticals Inc
- 27th September 1996
- 30th June 2003
- 9th March 2006
- Morphosys
- 25th March 2002
- 14th August 2002
- 11th November 2002
- 31st July 2003
- 8th March 2004
- 15th April 2004
- 25th August 2004
- 23rd December 2004
- 6th September 2005
- 28th February 2006
- Mylan Pharmaceuticals Inc
- Neurochem Inc
- 22nd December 2004
- 13th February 2006
- 18th April 2006
- Paradigm Therapeutics Ltd
- Pamgene International BV
- Pharmaceutical Product Development(PPD)
- Roche/Dade Behring
- Sangamo BioSciences Inc
- 6th June 2000
- 30th September 2004
- 15th December 2004
- 14th September 2005
- Sepracor Inc
- Serono
- Shire Pharmaceuticals/Synaptec Inc
- 30th November 1995
- 16th January 1996
- 1st April 2004
- Taisho Pharmaceutical Co Ltd
- Theratechnologies
- 3rd May 2001
- 17th December 2001
- 12th September 2002
- 25th September 2002
- 4th September 2003
- 21st December 2004
- Zeltia Group
- 10th August 2001
- 16th October 2001
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 4 - Key PHARMAC EUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
APPENDIX 5 - PRODUCT INDEX
|
